DIAGNOS Announces 2 screening clinics with Al Kahhal Medical Complex in KSA
DIAGNOS announced the implementation of DIAGNOS CARA (Computer Assisted Retina Analysis) telemedicine platform at Al Kahhal Medical Complex clinic. Al Kanhoor Medical Co, we will make retinal screening exams available to the diabetic population in the cities of Dammam and AL-Hasha Eastern Province of Saudi Arabia.
Read more - Market Wired
VLCC to launch wellness centres in Saudi Arabia
Beauty and wellness firm VLCC entered into a strategic partnership with Saudi healthcare services and products player Cigalah to launch VLCC wellness centres in the Kingdom of Saudi Arabia, starting with Jeddah. VLCC currently operates 20 wellness centres across UAE, Oman, Bahrain, Qatar and Kuwait and the company said its entry into Saudi Arabia will further strengthen its position in the Gulf Cooperation Council (GCC) region.
Read more – Business Standard
$55bn healthcare projects coming up in MENA
Healthcare projects worth $55.2 billion are currently in the pipeline in the Middle East and North Africa (Mena) region, according to latest industry estimates. A total of 37 mega hospital projects worth about $28.2 billion are already under way in the Gulf region, and these are expected to add 22,500 hospital beds to existing capacity, according to Alpen Capital Healthcare Report.
Read more – Trade Arabia
Oman's health expenditure declines by 11% y/y in 2016
Oman's Ministry of Health (MoH) has released its health status report for 2016, showing a decline in public health expenditure of 11% year on year (y/y) to OMR792.9 million (USD2 billion). The report also highlighted a notable decline in the number of infection incidents related to infectious diseases, owing to the ministry's highly responsive strategies to combat their spread.
Read more – Export.gov
BCC Canadian Bioceutical to enter into joint venture with Israeli Panaxia Pharmaceutical Industries
The Canadian Bioceutical Corp. has signed a term sheet outlining the binding conditions under which it will enter into a joint venture (JV) agreement with Panaxia Pharmaceutical Industries Ltd. Under the terms of the agreement, Panaxia will be providing proprietary, smokeless, pharma-grade cannabis-based products that have been proven to be in high demand, but have not been readily available in the United States.
Read more – Global Newswire
DHA launches second smart pharmacy
The Dubai Health Authority (DHA) inaugurated on Wednesday a smart pharmacy with a robot for dispensing and prescribing medication in Dubai Hospital. This is the second of its kind in the DHA, as the authority launched a smart pharmacy at Rashid Hospital last January. The robot can store up to 35,000 medicines and dispenses around 12 prescriptions in less than one minute.
Read more – DHA
FedEx introduces new cold shipping solution for healthcare industry in South Africa
Transport company, FedEx Express has introduced a new temperature-controlled solution, FedEx Cold Shipping, in South Africa. The FedEx Cold Shipping Solution includes cold shipping packaging for goods which require a refrigerated environment and can maintain constant 2–8°C environment inside the package for up to 48 hours for the standard duration box and up to 96 hours for the extended duration box.
Read more – We Care
US based pharmaceutical sets up first subsidiary in Rwanda
L.E.A.F. Pharmaceuticals LLC, a global pharmaceutical company, announced it is setting foot in Rwanda as L.E.A.F. Rwanda Ltd, a biotechnology company will be headquartered in Kigali. The company expects to focus on establishing Rwanda as a hub for biotechnology Research and Development (R&D) as well as pharmaceutical manufacturing in Africa.
Read more – New Times
South Africa grows share of global nuclear medicine market
South Africa currently has the largest body of nuclear medicine practitioners and nuclear medicine centres in sub-Saharan Africa, including nuclear medicine departments at 12 tertiary state hospitals. Pelindaba-based SouthAfrican company NTP Radioisotopes, a subsidiary of Necsa, currently, with global partnership agreements, supplies between a quarter and a third of the entire global demand of Mo-99. The group’s role has become even more significant with the 2016 exit of the Canadian NRU reactor from production.
Read more – CBN
Gilead intends producing new drug for virus C relapses
American pharmaceutical company Gilead asked the Egyptian Ministry of Health to register a new drug to treat cases that have not been treated with other virus C treatments, such as Sovaldi and Harvoni. Gilead will seek to provide the new medicine at an affordable price to the Egyptian citizen, especially as it will be used to treat relapsing patients with both virus C and C-cystic fibrosis, said Ahmed Afifi, head of strategic planning, access operations, and emerging markets for Latin America, Africa, and Asia Pacific regions at Gilead Sciences.
Read more – MENA FN